Artrya (ASX: AYA) — Company Overview, News & Financial Data
Artrya is a medical technology company focused on commercializing artificial intelligence software solutions for the early detection, diagnosis, and management of coronary artery disease.
Artrya
Artrya is a medical technology company focused on commercializing artificial intelligence software solutions for the early detection, diagnosis, and management of coronary artery disease. The company develops software designed to analyze coronary computed tomography angiography scans within minutes, identifying and quantifying arterial plaque features and stenosis to assist physicians in risk-stratifying chest pain patients. Its core product portfolio supports clinical decision-making in emergency departments, primary care, and cardiology clinics by providing automated non-invasive cardiovascular imaging insights. The company operates globally across clinical, regulatory, and commercial development pathways with regulatory approvals in Australia and clearance in the United States.
Snapshot
Operations
Products and/or services of Artrya
- AI Coronary Angiography Analysis: Cloud-based artificial intelligence platform analyzing coronary computed tomography angiography scans within minutes, detecting and quantifying coronary artery disease, stenosis, and plaque composition to assist clinicians in evaluating acute and atypical chest pain.
- United States Commercial Operations: FDA 510(k)-cleared cardiovascular software application integrated into American hospital emergency departments and outpatient clinical workflows, enabling non-invasive identification, plaque characterization, and risk stratification for acute care chest pain evaluation.
- Emergency Department Triage Solutions: Rapid decision support software for hospital emergency departments and primary care centers, enabling rapid rule-out of non-ischemic chest pain patients to minimize unnecessary hospital admissions, prolonged observation, and redundant diagnostic procedures.
- Coronary Plaque Quantification Software: Medical imaging diagnostic software that automatically detects, categorizes, and quantifies vulnerable arterial plaque types, including low-attenuation plaque and high-risk morphological features, supporting personalized treatment planning and preventive cardiovascular clinical management.
- Regulatory and Clinical Approvals: Clinical validation programs maintaining medical device registrations on the Australian Register of Therapeutic Goods and clearance from the United States Food and Drug Administration to support commercial distribution across international healthcare markets.
- Enterprise PACS System Integration: Cloud software architecture providing integration with picture archiving and communication systems and electronic health records, delivering automated chest pain evaluation reports directly into existing radiologist reading workstations and enterprise workflows.
Artrya executive team
- Mr. Bernard William Ridgeway F.A.C.I.D.Executive Chair
- Mr. John Konstantopoulos B.E.Co-Founder & CEO
- Mr. Richard Mark JarvisChief Financial Officer
- Phil BowenChief Operations Officer
- Prof. Girish Dwivedi M.D.Chief Scientific Officer
- Dr. Richard M. StewartChief Regulatory Affairs & Quality Officer
- Ryan AthearnHead of Global Clinical Operations
- Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A.Company Secretary